How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

16,936 results for

HIV Course

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Non-Neutralizing Antibodies Alter the Course of HIV-1 Infection in Vivo Full Text available with Trip Pro

not neutralize, the reporter virus in vitro. However, anti-HA protects against infection in humanized mice and strongly selects for nnAb-resistant viruses in an entirely Fc-dependent manner. Similar results were also obtained with tier 2 HIV-1 viruses using a human anti-gp41 nnAb, 246D. While nnAbs are demonstrably less effective than broadly neutralizing antibodies (bNAbs) against HIV-1 in vitro and in vivo, the data show that nnAbs can protect against and alter the course of HIV-1 infection in vivo (...) Non-Neutralizing Antibodies Alter the Course of HIV-1 Infection in Vivo Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial. To investigate the role of nnAbs on HIV-1 infection in vivo, we devised a replication-competent HIV-1 reporter virus that expresses a heterologous HA-tag on the surface of infected cells and virions. Anti-HA antibodies bind to, but do

2017 Cell

102. Child Sexual Abuse and HIV-Related Substance Use and Sexual Risk Across the Life Course Among Males and Females Full Text available with Trip Pro

Child Sexual Abuse and HIV-Related Substance Use and Sexual Risk Across the Life Course Among Males and Females Child sexual abuse is associated with substance use and sexual risk behaviors during adolescence and adulthood, but no known studies have documented associations across the life course in a nationally representative U.S.We used the National Longitudinal Study of Adolescent to Adult Health to measure associations between child sexual abuse and substance use and sexual risk behaviors (...) during adolescence, young adulthood, and adulthood among males and females (n = 11,820). Approximately 10% of females and 7% of males reported child sexual abuse. Associations with substance use were strongest during adolescence and lessened over time. Increased odds of sexual risk among those with a history of child sexual abuse remained consistent through the life course. Significant gender differences existed for some associations (e.g., adulthood multiple partners: males adjusted odds ratio (AOR

2017 Journal of child sexual abuse

103. Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients

Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients (IMPAACT4TB) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our

2017 Clinical Trials

104. Short-course TLR9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals with HIV infection. Full Text available with Trip Pro

Short-course TLR9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals with HIV infection. Treatment with latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcription in vivo but leads to only modest reductions in the size of the reservoir, possibly due to insufficient immune-mediated elimination of infected cells. We hypothesized that a single drug molecule-a novel Toll-like receptor 9 (TLR9) agonist, MGN1703-could function (...) as an enhancer of innate immunity and an LRA in vivo.We conducted a single-arm, open-label study in which 15 virologically suppressed HIV-1-infected individuals on antiretroviral therapy received 60 mg MGN1703 subcutaneously twice weekly for 4 weeks. We characterized plasmacytoid dendritic cell, natural killer (NK), and T-cell activation using flow cytometry on baseline and after 4 weeks of treatment. HIV-1 transcription was quantified by measuring plasma HIV-1 RNA during MGN1703 administration.In accordance

2017 Clinical Infectious Diseases

105. Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model Full Text available with Trip Pro

Quantification system for the viral dynamics of a highly pathogenic simian/human immunodeficiency virus based on an in vitro experiment and a mathematical model Developing a quantitative understanding of viral kinetics is useful for determining the pathogenesis and transmissibility of the virus, predicting the course of disease, and evaluating the effects of antiviral therapy. The availability of data in clinical, animal, and cell culture studies, however, has been quite limited. Many studies (...) of virus infection kinetics have been based solely on measures of total or infectious virus count. Here, we introduce a new mathematical model which tracks both infectious and total viral load, as well as the fraction of infected and uninfected cells within a cell culture, and apply it to analyze time-course data of an SHIV infection in vitro.We infected HSC-F cells with SHIV-KS661 and measured the concentration of Nef-negative (target) and Nef-positive (infected) HSC-F cells, the total viral load

2012 Retrovirology

106. Long-term follow-up after voluntary human immunodeficiency virus/sexually transmitted infection counseling, point-of-service testing, and referral to substance abuse treatment from the emergency department. (Abstract)

Long-term follow-up after voluntary human immunodeficiency virus/sexually transmitted infection counseling, point-of-service testing, and referral to substance abuse treatment from the emergency department. Public health initiatives have lowered human immunodeficiency virus (HIV) transmission risk associated with injection drug use in the United States, making sexual risk behaviors a greater source of transmission. Strategies are therefore needed to reduce these risk behaviors among all (...) emergency department (ED) patients who use drugs, regardless of route of administration. Although recent articles have focused on the opportunity for early HIV detection and treatment through an array of ED screening and testing strategies, the effect of voluntary HIV testing and brief counseling (VT/C) on the sexual behaviors of out-of-treatment drug users over time has not yet been reported.From November 2004 to May 2008, the study screened 46,208 urban ED patients aged 18 to 54 years; 2,148 (4.6

2012 Academic Emergency Medicine Controlled trial quality: uncertain

107. HIV Course

HIV Course HIV Course Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 HIV Course HIV Course Aka: HIV Course , HIV Stage , HIV Staging (...) received no therapy Course over following 18-24 months Risk of occult infection or death: <5% Slow decline in s (40 to 80 cells/year) VI. Staging: Intermediate Disease (CD4 Count 200 - 500 cells) HIV related disorders Pronounced , Recurrent Infection Recurrent Infection Pruritic Recurrent s Anogenital ulcers or warts Complications Atypical in this stage Management therapy is continued from prior stages Course (Untreated) over following 18-24 months Risk of occult infection or death: 20-30% Treatment

2018 FP Notebook

108. Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients. Full Text available with Trip Pro

Clinical Course, Radiological Manifestations, and Outcome of Pneumocystis jirovecii Pneumonia in HIV Patients and Renal Transplant Recipients. Pneumocystis jirovecii pneumonia (PCP) is a frequent opportunistic infection in immunocompromised patients. In literature, presentation and outcome of PCP differs between patients with human immunodeficiency virus (HIV) infection and renal transplant recipients (RTRs).We conducted a cross-sectional study of patients with PCP based on the HIV and renal (...) groups. Duration from illness onset to hospital presentation was longer in the HIV patients (median of 18 vs. 10 days (p = 0.02)), implying a less fulminant clinical course. Sixty percent of PCP cases in RTRs occurred >12 months after transplantation. Lengths of hospitalization, admission rates to the intensive care unit, and requirements for mechanical ventilation were similar. Outcome in both groups was favourable.While important differences in radiological presentation of PCP between HIV patients

2016 PLoS ONE

109. Persistent accumulation of gut macrophages with impaired phagocytic function correlates with simian immunodeficiency virus disease progression Full Text available with Trip Pro

Persistent accumulation of gut macrophages with impaired phagocytic function correlates with simian immunodeficiency virus disease progression The contribution of macrophages in the gastrointestinal tract to disease control or progression in HIV infection remains unclear. To address this question, we analyzed CD163+ macrophages in ileum and mesenteric lymph nodes (LN) from SIV-infected rhesus macaques with dichotomous expression of controlling MHC class I alleles predicted to be SIV controllers (...) function relative to controllers and uninfected macaques, and the proportion of phagocytic macrophages negatively correlated with mucosal epithelial breach, lamina propria Escherichia coli density, and plasma virus burden. Macrophages in intestine produced low levels of cytokines regardless of disease course, while mesenteric LN macrophages from progressors became increasingly responsive as infection advanced. These data indicate that noninflammatory CD163+ macrophages accumulate in gut mucosa

2017 European journal of immunology

110. Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction Full Text available with Trip Pro

Pathogenic Correlates of Simian Immunodeficiency Virus-Associated B Cell Dysfunction We compared and contrasted pathogenic (in pig-tailed macaques [PTMs]) and nonpathogenic (in African green monkeys [AGMs]) SIVsab infections to assess the significance of the B cell dysfunction observed in simian (SIV) and human immunodeficiency virus (HIV) infections. We report that the loss of B cells is specifically associated with the pathogenic SIV infection, while in the natural hosts, in which SIV (...) cell subsets point to their role in the pathogenesis of HIV/SIV infections and suggest that monitoring B cells may be a reliable approach for assessing disease progression.IMPORTANCE We report here that the HIV/SIV-associated B cell dysfunction (defined by loss of total and memory B cells, increased B regulatory cell [Breg] counts, and B cell activation and apoptosis) is specifically associated with pathogenic SIV infection and absent during the course of nonpathogenic SIV infection in natural

2017 Journal of virology

111. Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. Full Text available with Trip Pro

Killer-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women. Killer-cell Immunoglobulin-like Receptors (KIR) interact with Human Leukocyte Antigen (HLA) to modify natural killer- and T-cell function. KIR are implicated in HIV acquisition by small studies that have not been widely replicated. A role for KIR in HIV disease progression is more widely replicated and supported by functional studies.To assess the role of KIR (...) and KIR ligands in HIV acquisition and disease course, we studied at-risk women in South Africa between 2004-2010. Logistic regression was used for nested case-control analysis of 154 women who acquired vs. 155 who did not acquire HIV, despite high exposure. Linear mixed-effects models were used for cohort analysis of 139 women followed prospectively for a median of 54 months (IQR 31-69) until 2014.Neither KIR repertoires nor HLA alleles were associated with HIV acquisition. However, KIR haplotype BB

2016 BMC Infectious Diseases

112. HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. Full Text available with Trip Pro

HIV after 40 in rural South Africa: A life course approach to HIV vulnerability among middle aged and older adults. South Africa has the highest number of people living with HIV in the world (over 6 million) as well as a rapidly aging population, with 15% of the population aged 50 and over. High HIV prevalence in rural former apartheid homeland areas suggests substantial aging with HIV and acquisition of HIV at older ages. We develop a life course approach to HIV vulnerability, highlighting (...) the rise and fall of risk and protection as people age, as well as the role of contextual density in shaping HIV vulnerability. Using this approach, we draw on an innovative multi-method data set collected within the Agincourt Health and Demographic Surveillance System in South Africa, combining survey data with 60 nested life history interviews and 9 community focus group interviews. We examine HIV risk and protective factors among adults aged 40-80, as well as how and why these factors vary among

2015 Social Science & Medicine

113. Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study. Full Text available with Trip Pro

Delays to anti-tuberculosis treatment intiation among cases on directly observed treatment short course in districts of southwestern Ethiopia: a cross sectional study. Delayed tuberculosis (TB) diagnosis and treatment increase morbidity, mortality, expenditure, and transmission in the community. This study assessed patient and provider related delays to diagnosis and treatment of TB.A cross-sectional study was conducted among 735 new adult TB cases registered between January to December 2015 (...) predictors of delays and statistical significance was judged at p < 0.05.The median (inter-quartile range) of patient, provider and total delays were 25 (IQR;15-36), 22 (IQR:9-48) and 55 (IQR:32-100) days, respectively. More than half (54.6%) of the total delay was attributed to health system. Prior self-treatment [adjusted Odds Ratio (aOR)]: 1.72, 95% confidence interval [CI]:1.07-2.75), HIV co-infection (aOR:1.8, 95% CI: 1.05-3.10) and extra-pulmonary TB (aOR: 1.54,95% CI:1.03-2.29) were independently

2019 BMC Infectious Diseases

114. Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. Full Text available with Trip Pro

Timing of treatment interruption among latently infected tuberculosis cases treated with a nine-month course of daily isoniazid: findings from a time to event analysis. Treatment of latent tuberculosis infection (LTBI) in high-risk groups is an effective strategy for TB control and elimination in low incidence settings. A nine-month course of daily isoniazid (INH) has been the longest prescribed therapy; however, completion rates are suboptimal. We need data to guide TB program outreach efforts (...) , 0.81), patients with diabetes (HR = 0.77, 95% CI: 0.60, 0.98), and patients with HIV (HR = 0.39, 95% CI: 0.30, 0.51) had a lower risk of treatment default. However, black patients (HR = 1.57, 95% CI: 1.44, 1.70), Hispanic patients (HR = 1.54, 95% CI: 1.43, 1.66), and non-U.S.-born persons living in the United States ≤5 years (HR = 1.25, 95% CI: 1.18, 1.32) were significantly more likely to default on therapy.In this analysis of INH treatment outcome, we see high levels of treatment discontinuation

2019 BMC Public Health

115. Therapeutic guidelines for antiretroviral (ARV) treatment of adult HIV infection

of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011; 365:1482-1491. 33. Meintjes G, Wilkinson R, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis- associated immune reconstitution inflammatory syndrome. AIDS 2010; 24:2381-2390. 34. Torok ME, Nguyen TB, Tran THC, et al Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374. 35. Hughes JP (...) diagnosis and when the patient is ready to start the therapy (C-III). There is no CD4 cell count threshold above which starting therapy is contraindicated and no demonstrated harm of early ART initiation. Ongoing observational cohorts continue to accumulate data confirming that the benefits of HIV treatment are maximized when it is started earlier in the course of the disease: • A combined analysis of 6699 ART-treated individuals in the Multicenter AIDS Cohort Study (MACS) and the Women’s Interagency

2020 CPG Infobase

116. Guidance for the use of post-exposure prophylaxis (PEP) for the prevention of HIV in British Columbia

care providers caring for persons who have experienced significant exposure to blood and/or body fluids in the work place or community setting. The risk of Human Immunodeficiency Virus (HIV) acquisition from a given exposure depends on the likelihood the source has transmissible HIV infection, and the biological risk of HIV transmission based on the exposure that has occurred. This guideline is designed to deal specifically with exposures to HIV and is not applicable to other exposures (...) -arv-guidelines/0 Toronto General Hospital, University Health Network Immunodeficiency Clinic. HIV/HCV Drug Therapy Guide. http://app.hivclinic.ca/ 19 XI REFERENCES 1. Kuhar DT, Henderson DK, Struble KA, et al. for the US Public Health Service Working Group. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis. Infect Control Hosp Epidemiol 2013; 34: 875-92 2. Centers for Disease

2020 CPG Infobase

117. A Prospective Time Course Study on Serological Testing for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus with Blood Samples Taken up to 48 Hours After Death. Full Text available with Trip Pro

A Prospective Time Course Study on Serological Testing for Human Immunodeficiency Virus, Hepatitis B Virus and Hepatitis C Virus with Blood Samples Taken up to 48 Hours After Death. The transmission of viral and non-viral infectious pathogens continues to be the most serious of the potential adverse effects of allogenic tissue transplantations. EU Directive 2006/17/EC stipulates that cadaveric blood specimens for serology testing in the context of post-mortem tissue donation must be taken (...) not later than 24 h post-mortem. An expanded time slot would significantly improve the availability of tissue donations, but there are no significant data on the stability of infectious serology assays for anti-human immunodeficiency virus (HIV), anti-hepatitis C virus (HCV), hepatitis B virus (HBV) surface antigen (HBsAg) and anti-HBC core antigen (HBc) in samples collected more than 24 h post-mortem. In this prospective study, serum samples of 30 deceased persons were taken upon admission

2011 Journal of Medical Microbiology

118. Women?s health in NSW ? a life course approach

and obesity exacerbate the features of this condition 49 • Increased uptake of cervical screening is argued to be the best health behaviour to prevent against cervical cancer 50 alongside the Human Papilloma Virus vaccination program for adolescent women 51 • Over half (55.1%) of young women in NSW take up biennial cervical cancer screening. This rate has remained steady since 2003 52 • Women who are obese, reliant on welfare, current smokers, report childhood sexual abuse, and experience anxiety symptoms (...) Women?s health in NSW ? a life course approach Women’s health in NSW – a life course approach: a rapid review A Steel J Frawley A Dobson C Jackson J Lucke L Tooth W Brown J Byle G Mishra An Evidence Check review brokered by the Sax Institute for the NSW Ministry of Health March 2013 This report was prepared by: Amie Steel, Jane Frawley, Annette Dobson, Caroline Jackson, Jayne Lucke, Leigh Tooth, Wendy Brown, Julie Byles and Gita Mishra Centre for Research Excellence in Women’s Health in the 21

2013 Sax Institute Evidence Check

119. Financial education for HIV?vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence Full Text available with Trip Pro

Financial education for HIV?vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence Financial education for HIV‐vulnerable youth, orphans, and vulnerable children: A systematic review of outcome evidence - Lee - 2020 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Financial education for HIV (...) of Use. Shareable Link Use the link below to share a full-text version of this article with your friends and colleagues. Copy URL Share a link Share on 1 Children and youth are defined as those between 0 and 24 years by UN and UNICEF definitions ( , , retrieved on November 15, 2017). HIV is the leading cause of youth mortality in Africa, and the second cause of death among young people worldwide (UNAIDS, ; WHO, ). Young girls are particularly vulnerable (Fleischman & Peck, ), accounting for 20

2020 Campbell Collaboration

120. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

Assessment, Development and Evaluation HPV Human papilloma virus ICER Incremental cost-effectiveness ratio ICO Istituto Catala' d'Oncologia (Spain) LY Life years 9vHPV Nine-valent HPV vaccine PeIN Penile intraepithelial neoplasia PICO Population Intervention Comparison Outcome POTS Postural orthostatic tachycardia syndrome QALY Quality-adjusted life years 6MPI Six-month persistent infection VaIN Vaginal intraepithelial neoplasia VLP Virus-like particle VIN Vulvar intraepithelial neoplasia Glossary Cost (...) the most favorable conditions, e.g. experimental setting. Vaccine hesitancy Delay in acceptance or refusal of vaccines despite availability of vaccination services. Viroprevalence Prevalence of virus in population. SCIENTIFIC ADVICE Guidance on HPV vaccination in EU countries: focus on boys, PLHIV and 9-valent HPV vaccine introduction 1 Executive summary Scope This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas: efficacy/effectiveness of the 9-valent HPV

2020 European Centre for Disease Prevention and Control - Technical Guidance

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>